Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

Fani KaragianniChristina PiperiVassiliki MpakouAris SpathisPeriklis G FoukasMaria DalamagaVasiliki PappaEvangelia Papadavid

Published in: PloS one (2021)

The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
drug delivery